

Benny V Jensen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8310033/publications.pdf>

Version: 2024-02-01

64

papers

3,812

citations

279798

23

h-index

144013

57

g-index

64

all docs

64

docs citations

64

times ranked

5576

citing authors

#	ARTICLE	IF	CITATIONS
1	Randomized phase 2 study of nivolumab with or without ipilimumab in combination with stereotactic body radiotherapy in patients with refractory metastatic pancreatic cancer (CHECKPAC).. Journal of Clinical Oncology, 2022, 40, 554-554.	1.6	1
2	A Randomized Placebo-Controlled Phase 2 Study of Gemcitabine and Capecitabine with or without T-ChOS as Adjuvant Therapy in Patients with Resected Pancreatic Cancer (CHIPAC). Pharmaceutics, 2022, 14, 509.	4.5	2
3	Pre- and Perioperative Inflammatory Biomarkers in Older Patients Resected for Localized Colorectal Cancer: Associations with Complications and Prognosis. Cancers, 2022, 14, 161.	3.7	9
4	Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Lancet Oncology, The, 2022, 23, 659-670.	10.7	282
5	Randomized Phase II Study of Nivolumab With or Without Ipilimumab Combined With Stereotactic Body Radiotherapy for Refractory Metastatic Pancreatic Cancer (CheckPAC). Journal of Clinical Oncology, 2022, 40, 3180-3189.	1.6	29
6	Circulating Protein Biomarkers for Prognostic Use in Patients with Advanced Pancreatic Ductal Adenocarcinoma Undergoing Chemotherapy. Cancers, 2022, 14, 3250.	3.7	4
7	Cetuximab plus irinotecan administered biweekly with reduced infusion time to heavily pretreated patients with metastatic colorectal cancer and related <scp><i>RAS</i></scp> and <scp><i>BRAF</i></scp> mutation status. International Journal of Cancer, 2021, 148, 2542-2556.	5.1	4
8	Pre-treatment serum vitamin D deficiency is associated with increased inflammatory biomarkers and short overall survival in patients with pancreatic cancer. European Journal of Cancer, 2021, 144, 72-80.	2.8	17
9	Circulating Protein Biomarkers for Use in Pancreatic Ductal Adenocarcinoma Identification. Clinical Cancer Research, 2021, 27, 2592-2603.	7.0	14
10	Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial. Lancet Oncology, The, 2021, 22, 665-677.	10.7	110
11	Cell-free DNA promoter hypermethylation as a diagnostic marker for pancreatic ductal adenocarcinoma “ An external validation study. Pancreatology, 2021, 21, 1081-1091.	1.1	4
12	Response to the letter entitled: Re: Pre-treatment serum vitamin D deficiency is associated with increased inflammatory biomarkers and short overall survival in patients with pancreatic cancer. European Journal of Cancer, 2021, 158, 248-250.	2.8	0
13	Clinical value of serum hyaluronan and propeptide of type III collagen in patients with pancreatic cancer. International Journal of Cancer, 2020, 146, 2913-2922.	5.1	41
14	Prognostic Value of Combined Detection of Serum IL6, YKL-40, and C-reactive Protein in Patients with Unresectable Pancreatic Cancer. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 176-184.	2.5	12
15	Prognostic impact of Charlson’s Age-Comorbidity Index and other risk factors in patients with pancreatic cancer. European Journal of Cancer Care, 2020, 29, e13219.	1.5	19
16	Antitumour immunity invoked by hepatic arterial infusion of first-line oxaliplatin predicts durable colorectal cancer control after liver metastasis ablation: 8 “ 12 % years of follow-up. International Journal of Cancer, 2020, 146, 2019-2026.	5.1	14
17	ABCG2 Protein Levels and Association to Response to First-Line Irinotecan-Based Therapy for Patients with Metastatic Colorectal Cancer. International Journal of Molecular Sciences, 2020, 21, 5027.	4.1	7
18	Pembrolizumab in Microsatellite-Instability “ High Advanced Colorectal Cancer. New England Journal of Medicine, 2020, 383, 2207-2218.	27.0	1,513

#	ARTICLE	IF	CITATIONS
19	Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 Study.. Journal of Clinical Oncology, 2020, 38, LBA4-LBA4.	1.6	150
20	Prognostic and predictive value of circulating DNA for hepatic arterial infusion of chemotherapy for patients with colorectal cancer liver metastases. Molecular and Clinical Oncology, 2020, 13, 1-1.	1.0	6
21	A systematic review of observational studies of trifluridine/tipiracil (TAS-102) for metastatic colorectal cancer. Acta Oncol ³ gica, 2019, 58, 1149-1157.	1.8	34
22	Intrahepatic Oxaliplatin and Systemic 5-FU +/“ Cetuximab in Chemo-Na~ve Patients with Liver Metastases from Colorectal Cancer. Oncology, 2019, 96, 299-308.	1.9	2
23	The effect of postoperative gemcitabine on overall survival in patients with resected pancreatic cancer: A nationwide population-based Danish register study. Acta Oncol ³ gica, 2019, 58, 864-871.	1.8	19
24	An open label phase 1 study evaluation safety, tolerability, and maximum tolerated dose of oral administration of irinotecan in combination with capecitabine. Cancer Chemotherapy and Pharmacology, 2019, 84, 441-446.	2.3	3
25	Associations between primary tumor <i>RAS</i>, <i>BRAF</i> and <i>PIK3CA</i> mutation status and metastatic site in patients with chemo-resistant metastatic colorectal cancer. Acta Oncol ³ gica, 2018, 57, 1057-1062.	1.8	24
26	Systemic immune response induced by oxaliplatin-based neoadjuvant therapy favours survival without metastatic progression in high-risk rectal cancer. British Journal of Cancer, 2018, 118, 1322-1328.	6.4	26
27	Total cell-free DNA, carcinoembryonic antigen, and C-reactive protein for assessment of prognosis in patients with metastatic colorectal cancer. Tumor Biology, 2018, 40, 101042831881120.	1.8	10
28	Measuring KRAS Mutations in Circulating Tumor DNA by Droplet Digital PCR and Next-Generation Sequencing. Translational Oncology, 2018, 11, 1220-1224.	3.7	63
29	Prognostic value of serum interleukin-6 and YKL-40 and systemic inflammatory response in patients with unresectable pancreatic cancer.. Journal of Clinical Oncology, 2018, 36, 267-267.	1.6	0
30	Prognostic and diagnostic value of serum hyaluronan in patients with pancreatic carcinoma.. Journal of Clinical Oncology, 2018, 36, e16249-e16249.	1.6	1
31	Topoisomerase I copy number alterations as biomarker for irinotecan efficacy in metastatic colorectal cancer. BMC Cancer, 2017, 17, 48.	2.6	17
32	Risk factors for brain metastases in patients with metastatic colorectal cancer. Acta Oncol ³ gica, 2017, 56, 639-645.	1.8	26
33	Cell-Free DNA in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis. Oncologist, 2017, 22, 1049-1055.	3.7	73
34	Capecitabine and Oxaliplatin Before, During, and After Radiotherapy for High-Risk Rectal Cancer. Clinical Colorectal Cancer, 2017, 16, e7-e14.	2.3	10
35	The prognostic value of serum CA 19-9 in patients with metastatic colorectal cancer.. Journal of Clinical Oncology, 2017, 35, e15131-e15131.	1.6	1
36	Ultrasensitive plasma ctDNA <i>KRAS</i> assay for detection, prognosis, and assessment of therapeutic response in patients with unresectable pancreatic ductal adenocarcinoma. Oncotarget, 2017, 8, 97769-97786.	1.8	28

#	ARTICLE	IF	CITATIONS
37	The prognostic value of serum IL-6 and YKL-40 in patients with metastatic colorectal cancer.. Journal of Clinical Oncology, 2017, 35, e15060-e15060.	1.6	0
38	Early ¹⁸ F-FDG-PET/CT as a predictive marker for treatment response and survival in patients with metastatic colorectal cancer treated with irinotecan and cetuximab. Acta Oncologica, 2016, 55, 1175-1182.	1.8	4
39	Seeding after ultrasound-guided percutaneous biopsy of liver metastases in patients with colorectal or breast cancer. Acta Oncologica, 2016, 55, 638-643.	1.8	16
40	The potential diagnostic value of serum microRNA signature in patients with pancreatic cancer. International Journal of Cancer, 2016, 139, 2312-2324.	5.1	33
41	Outcome of cetuximab plus irinotecan in relation to <i>RAS</i> and <i>BRAF</i> mutational status in patients with colorectal cancer prior treated with a fluoropyrimidine, oxaliplatin and irinotecan.. Journal of Clinical Oncology, 2016, 34, e15115-e15115.	1.6	0
42	MicroRNA Expression in Formalin-fixed Paraffin-embedded Cancer Tissue: Identifying Reference MicroRNAs and Variability. BMC Cancer, 2015, 15, 1024.	2.6	27
43	Improved survival with early adjuvant chemotherapy after colonic resection for stage III colonic cancer: A nationwide study. Journal of Surgical Oncology, 2015, 112, 538-543.	1.7	27
44	FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study. Gut, 2015, 64, 921-928.	12.1	22
45	Clinical utility of KRAS status in circulating plasma DNA compared to archival tumour tissue from patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor therapy. European Journal of Cancer, 2015, 51, 2678-2685.	2.8	48
46	Comparative circulating tumor DNA levels for <i>KRAS</i> mutations in patients with nonresectable pancreatic cancer.. Journal of Clinical Oncology, 2015, 33, 288-288.	1.6	2
47	Prognostic value of plasma circulating tumor (ct) DNA KRAS mutations and serum CA19-9 in unresectable pancreatic cancer (PC) patients.. Journal of Clinical Oncology, 2015, 33, 4022-4022.	1.6	1
48	miR-345 in Metastatic Colorectal Cancer: A Non-Invasive Biomarker for Clinical Outcome in Non-KRAS Mutant Patients Treated with 3rd Line Cetuximab and Irinotecan. PLoS ONE, 2014, 9, e99886.	2.5	68
49	MicroRNA Biomarkers in Whole Blood for Detection of Pancreatic Cancer. JAMA - Journal of the American Medical Association, 2014, 311, 392.	7.4	380
50	A systematic review of salvage therapy to patients with metastatic colorectal cancer previously treated with fluorouracil, oxaliplatin and irinotecan +/~ targeted therapy. Cancer Treatment Reviews, 2014, 40, 701-715.	7.7	64
51	Tissue MicroRNAs as Predictors of Outcome in Patients with Metastatic Colorectal Cancer Treated with First Line Capecitabine and Oxaliplatin with or without Bevacizumab. PLoS ONE, 2014, 9, e109430.	2.5	39
52	Seeding after biopsy of liver metastases in patients with primary colorectal and breast cancer.. Journal of Clinical Oncology, 2014, 32, e14545-e14545.	1.6	0
53	Primary tumor location and expression of mir-664 as a combined biomarker for bevacizumab effectiveness in metastatic colorectal cancer.. Journal of Clinical Oncology, 2013, 31, 3572-3572.	1.6	2
54	Pretreatment plasma concentrations of YKL-40 and IL-6 in patients with pancreatic cancer: Potential diagnostic and prognostic biomarkers.. Journal of Clinical Oncology, 2013, 31, 164-164.	1.6	1

#	ARTICLE	IF	CITATIONS
55	Oxaliplatin given by hepatic arterial infusion (HAI) or systemic (SYS) with capecitabine in patients (pts) with unresectable liverlimited metastasis (Ur-LLM) from colorectal cancer (CRC).. Journal of Clinical Oncology, 2013, 31, e14593-e14593.	1.6	0
56	MicroRNA biomarkers in whole blood for detection of pancreatic cancer.. Journal of Clinical Oncology, 2013, 31, 4052-4052.	1.6	2
57	Observer variability in a phase II trial â€œ assessing consistency in RECIST application. Acta OncolÃ³gica, 2012, 51, 774-780.	1.8	17
58	Impact of microRNA miR-345 in blood on survival and response in 144 patients with metastatic colorectal cancer treated with third-line cetuximab and irinotecan.. Journal of Clinical Oncology, 2012, 30, 451-451.	1.6	1
59	Diagnostic microRNA serum profile in pancreatic cancer.. Journal of Clinical Oncology, 2012, 30, 160-160.	1.6	0
60	Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil. Acta OncolÃ³gica, 2007, 46, 697-701.	1.8	33
61	Re-treatment with cetuximab in patients with severe hypersensitivity reactions to cetuximab. Two case reports.. Acta OncolÃ³gica, 2006, 45, 1137-1138.	1.8	19
62	Cardiotoxic Consequences of Anthracycline-Containing Therapy in Patients With Breast Cancer. Seminars in Oncology, 2006, 33, 15-21.	2.2	298
63	High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer. Clinical Cancer Research, 2003, 9, 4423-34.	7.0	123
64	Increased prognostic value of combined myocardial perfusion imaging and exercise electrocardiography in patients with coronary artery disease. Journal of Nuclear Cardiology, 2000, 7, 616-622.	2.1	10